Head to Head Comparison: Amarin (AMRN) and Its Peers

Amarin (NASDAQ:AMRN) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Amarin to similar companies based on the strength of its valuation, dividends, earnings, analyst recommendations, institutional ownership, profitability and risk.

Insider & Institutional Ownership

22.3% of Amarin shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 4.2% of Amarin shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility and Risk

Amarin has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Amarin’s rivals have a beta of -3.76, suggesting that their average share price is 476% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Amarin and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2	1	0	0	1.33
Amarin Competitors	7777	13864	25737	1034	2.41

Amarin presently has a consensus target price of $13.00, suggesting a potential upside of 6.12%. As a group, “Pharmaceuticals” companies have a potential upside of 23.84%. Given Amarin’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Amarin has less favorable growth aspects than its rivals.

Profitability

This table compares Amarin and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarin	-10.87%	-0.52%	-0.36%
Amarin Competitors	-2,381.20%	-218.66%	-15.76%

Earnings and Valuation

This table compares Amarin and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Amarin	$213.65 million	-$38.80 million	-12.76
Amarin Competitors	$3.56 billion	$3.19 billion	548.12

Amarin’s rivals have higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Amarin rivals beat Amarin on 9 of the 13 factors compared.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.